Prof. David Christie
MBChB, FRANZCR, Radiation Oncologist
Languages Spoken
English
Overview
Clinical interests in urological (including prostate) cancers, and skin cancers plus benign conditions suitable for radiation therapy.
Professor David Christie is based on the Gold Coast and attends GenesisCare treatment centres at Tugun and Southport. He also attends clinics at Pindara Private Hospital and in Northern NSW (Ballina).
David qualified in Medicine from New Zealand’s University of Otago in 1987 and completed Radiation Oncology training in Sydney in 1995, at which time he moved to Queensland and commenced full-time practice. David has experience in treating many cancer types that require radiation therapy, however he has a clinical interest in urological cancers including prostate.
He has research and teaching roles with the University of New England as well as Bond and Griffith Universities. Special clinical interests include urological cancer (including prostate), skin cancer (including wide field radiotherapy), benign diseases (including dupuytren’s disease), lymphoma and patients eligible for clinical trials.
Until recently, he was an editor for the only Radiation Oncology medical journal that is based in Australia, JMIRO. He is currently the chair of the Faculty of Radiation Oncology Genitourinary Group (FROGG).
Consults at:
Tugun
Southport
Pindara Private Hospital
Ballina
Professional memberships
- Trans-Tasman Radiation Oncology Group (TROG)
- Journal of Medical Imaging & Radiation Oncology (former Editor)
- Bond University
- Griffith University
- University of New England
- Faculty of Radiation Oncology Genitourinary Group (FROGG)
Publications
- Professor Christie is an active contributor to several clinical trial organisations including TROG and has published over 180 publications which are accessible online.
- Andrew E. P., David C, Bradley W, Peter O’B., et al. & on behalf of the National Dermatology Radiation Oncology Registry (NDROR) investigators and sites (2022) ‘Preliminary efficacy and safety analysis: 12-month results in 83 patients using a novel approach of widefield radiation therapy for extensive skin field cancerization with or without keratinocyte cancers’